Publications by authors named "J S Spano"
Background: The Pseudomonas filamentous bacteriophage (Pf) infects Pseudomonas aeruginosa (Pa) and is abundant in the airways of many people with cystic fibrosis (CF) (pwCF). We previously demonstrated that Pf promotes biofilm growth, as well as generates liquid crystals that confer biofilms with adhesivity, viscosity and resistance to clearance. Consistent with these findings, the presence of Pf in sputum from pwCF has been linked to chronic Pa infection and more severe exacerbations in a cross-sectional cohort study.
View Article and Find Full Text PDFArticle Synopsis
- The older population makes up about 50%-60% of newly diagnosed cancer patients, making it essential to consider their specific healthcare needs.
- Older patients face higher risks of severe side effects from cancer treatments due to age-related factors and existing health conditions, leading to often being under-treated.
- The review highlights the importance of understanding cancer drug pharmacology and advocating a cautious treatment approach to minimize dangerous toxicities in older patients.
Article Synopsis
- * Using a cohort of over 3,600 participants, researchers measured levels of specific antibodies and assessed SARS-CoV-2 infection outcomes over the next six months.
- * Results showed that higher anti-Spike IgG antibody levels correlated with reduced infection risk in the control group, but this was not the case for individuals in specific patient populations.
Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study.
J Immunother Cancer
August 2024
Background: Immune checkpoint inhibitors (ICIs) have been a major advance in cancer management. However, we still lack prospective real-world data regarding their usage in people with HIV infection (PWH).
Methods: The ANRS CO24 OncoVIHAC study (NCT03354936) is an ongoing prospective observational cohort study in France of PWH with cancer treated with ICI.
Background And Aims: Bevacizumab-based chemotherapy is a recommended first-line treatment for metastatic colorectal cancer (mCRC). Robust biomarkers with clinical practice applicability have not been identified for patients with this treatment. We aimed to evaluate the prognostic yield of serum mid-infrared spectroscopy (MIRS) on patients receiving first-line bevacizumab-based chemotherapy for mCRC.
View Article and Find Full Text PDF